Table of Contents
Introduction
Eltrombopag is an oral thrombopoietin receptor agonist used to increase platelet production in selected patients with thrombocytopenia. It is marketed under the brand name Promacta in the United States and Revolade in some other countries. Pharmacologically, eltrombopag is classified as a non-peptide thrombopoietin receptor agonist.
Thrombopoietin, also called TPO, is the natural hormone that regulates platelet production. It acts on the thrombopoietin receptor, also known as c-Mpl, which is present on hematopoietic stem cells and megakaryocyte precursors in the bone marrow. Activation of this receptor promotes megakaryocyte proliferation, differentiation, and maturation, ultimately increasing platelet production.
Eltrombopag is clinically important because it helps raise platelet counts in disorders where platelet numbers are dangerously low. Current prescribing information lists eltrombopag for thrombocytopenia in persistent or chronic immune thrombocytopenia in adults and children 1 year and older who have had insufficient response to corticosteroids, immunoglobulins, or splenectomy; thrombocytopenia in chronic hepatitis C to allow initiation and maintenance of interferon-based therapy; severe aplastic anemia as first-line therapy in combination with standard immunosuppressive therapy; and severe aplastic anemia after insufficient response to immunosuppressive therapy.
For pharmacy, medical, nursing, and competitive exam students, eltrombopag is important because it is not a platelet transfusion, not a corticosteroid, and not an immunoglobulin. It works by stimulating platelet production through the TPO receptor pathway, mainly at the level of megakaryocytes and hematopoietic progenitor cells.
Mechanism of Action (Step-wise)
- Primary target: Thrombopoietin receptor
Eltrombopag targets the thrombopoietin receptor, also called TPO receptor or c-Mpl. This receptor is expressed on megakaryocyte precursors and hematopoietic stem cells in the bone marrow.
The TPO receptor is the main physiological receptor responsible for regulating platelet production.
- Binding to the transmembrane domain of c-Mpl
Eltrombopag interacts with the transmembrane domain of the human TPO receptor. This is an important exam point because eltrombopag does not bind to the exact same site as endogenous thrombopoietin. The official prescribing information states that eltrombopag interacts with the transmembrane domain of the human TPO receptor and initiates signaling cascades that induce megakaryocyte proliferation and differentiation.
- Activation of intracellular signaling
After eltrombopag activates the TPO receptor, intracellular signaling pathways are stimulated. These include pathways involved in hematopoietic cell growth, survival, proliferation, and differentiation.
Important signaling pathways include:
- JAK-STAT pathway
- MAPK pathway
- PI3K-AKT pathway
These pathways help bone marrow progenitor cells develop into mature megakaryocytes.
- Megakaryocyte proliferation
Megakaryocytes are large bone marrow cells responsible for producing platelets. Eltrombopag stimulates proliferation of megakaryocyte precursor cells.
This increases the number of cells available to mature into platelet-producing megakaryocytes.
- Megakaryocyte differentiation and maturation
In addition to proliferation, eltrombopag promotes differentiation and maturation of megakaryocytes. Mature megakaryocytes extend cytoplasmic fragments called proplatelets into bone marrow sinusoids.
These proplatelet fragments are released into circulation and become platelets.
- Increased platelet production
The final hematologic effect is increased platelet production. This helps raise circulating platelet counts and reduces bleeding risk in selected patients with thrombocytopenia.
However, eltrombopag is not used to normalize platelet counts completely. The goal is usually to raise platelet counts enough to reduce bleeding risk or allow necessary antiviral or immunosuppressive therapy.
- Effect in immune thrombocytopenia
In immune thrombocytopenia, platelets are destroyed by immune mechanisms and platelet production may also be inadequate. Eltrombopag increases platelet production from the bone marrow to help compensate for platelet destruction.
It is used when previous therapies such as corticosteroids, immunoglobulins, or splenectomy have not worked well enough.
- Effect in chronic hepatitis C-associated thrombocytopenia
In chronic hepatitis C, thrombocytopenia may occur due to liver disease, splenic sequestration, reduced thrombopoietin production, and bone marrow suppression. Eltrombopag can increase platelet counts enough to allow initiation or maintenance of interferon-based therapy in selected patients. The label specifically notes this use in chronic hepatitis C patients whose thrombocytopenia prevents or limits interferon-based therapy.
- Effect in severe aplastic anemia
In severe aplastic anemia, bone marrow failure leads to low blood cell counts. Eltrombopag stimulates hematopoietic progenitor cells through TPO receptor signaling. This may improve platelet production and, in some patients, can also support broader hematopoiesis involving red blood cells and white blood cells.
- Final therapeutic effect
The final therapeutic effect of eltrombopag is activation of the TPO receptor, stimulation of megakaryocyte proliferation and differentiation, increased platelet production, improved platelet counts, and reduced bleeding risk in selected thrombocytopenic conditions.
Pharmacokinetics
Eltrombopag is administered orally as tablets or powder for oral suspension, depending on patient age, dose needs, and formulation availability.
Absorption:
Eltrombopag is absorbed after oral administration. Its absorption is significantly affected by polyvalent cations such as calcium, magnesium, aluminum, iron, selenium, and zinc. These cations can chelate eltrombopag and reduce absorption.
This is a major exam point. Eltrombopag should be separated from antacids, dairy products, mineral supplements, and other products containing polyvalent cations.
Distribution:
Eltrombopag is highly protein-bound in plasma. After absorption, it reaches the bone marrow and stimulates TPO receptor signaling on megakaryocyte-lineage cells.
Metabolism:
Eltrombopag is metabolized mainly in the liver through several pathways, including oxidation, glucuronidation, and conjugation. Enzymes involved include CYP1A2, CYP2C8, UGT1A1, and UGT1A3.
Excretion:
Eltrombopag is eliminated mainly through feces, with a smaller portion eliminated in urine as metabolites. Unchanged drug is primarily recovered in feces.
Half-life and duration:
Eltrombopag has a long enough half-life to support once-daily dosing. Platelet response is not immediate because the drug works by stimulating megakaryocyte development and platelet production. Platelet counts usually rise gradually over 1 to 2 weeks.
Special pharmacokinetic point:
Because eltrombopag exposure can be affected by liver impairment, ethnicity, age, food, and drug interactions, dosing must be individualized. Liver function monitoring is especially important due to hepatotoxicity risk.
Clinical Uses
- Persistent or chronic immune thrombocytopenia:
Eltrombopag is used in adults and children 1 year and older with persistent or chronic immune thrombocytopenia who have had insufficient response to corticosteroids, immunoglobulins, or splenectomy. It should be used only when thrombocytopenia and clinical condition increase bleeding risk. - Thrombocytopenia in chronic hepatitis C:
Eltrombopag is used to treat thrombocytopenia in patients with chronic hepatitis C to allow initiation and maintenance of interferon-based therapy. - First-line severe aplastic anemia:
Eltrombopag is used with standard immunosuppressive therapy as first-line treatment for severe aplastic anemia. - Refractory severe aplastic anemia:
It is used in patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy. - Bleeding-risk reduction:
In ITP, the purpose is not to normalize platelets but to maintain a platelet count that reduces clinically important bleeding risk. - Bone marrow stimulation:
In aplastic anemia, eltrombopag can support hematopoietic progenitor cells and improve blood cell production in selected patients.
Adverse Effects
Common adverse effects of eltrombopag include:
- Nausea
- Diarrhea
- Headache
- Fatigue
- Cough
- Pyrexia
- Upper respiratory tract infection
- Nasopharyngitis
- Vomiting
- Abdominal pain
- Increased alanine aminotransferase
- Increased aspartate aminotransferase
- Anemia
- Rash
- Back pain
- Myalgia
Across indications, labeling lists common adverse reactions such as anemia, nausea, pyrexia, increased alanine aminotransferase, cough, fatigue, headache, and diarrhea.
Important serious or clinically significant adverse effects include:
- Hepatotoxicity
- Hepatic decompensation in chronic hepatitis C patients using interferon and ribavirin
- Thrombotic and thromboembolic complications
- Portal vein thrombosis
- Cataracts
- Bone marrow reticulin formation
- Increased risk of hematologic malignancy progression in some marrow disorders
- Severe cutaneous reactions
- Laboratory abnormalities
- Excessive platelet elevation
- Rebound thrombocytopenia after discontinuation
Eltrombopag carries an important warning for hepatic decompensation in patients with chronic hepatitis C when used with interferon and ribavirin, and it may increase the risk of severe or potentially life-threatening hepatotoxicity. Liver function should be monitored before and during treatment.
Thrombotic risk is another key exam point. If platelet counts become too high, the risk of thrombosis may increase. Therefore, eltrombopag dosing is adjusted to maintain platelets at the lowest level needed to reduce bleeding risk, not to produce normal or very high platelet counts.
Comparative Analysis
| Feature | Eltrombopag | Romiplostim | Avatrombopag | Platelet Transfusion |
|---|---|---|---|---|
| Brand example | Promacta, Revolade | Nplate | Doptelet | Not a drug class |
| Drug class | Oral TPO receptor agonist | Injectable TPO receptor agonist | Oral TPO receptor agonist | Blood component therapy |
| Main target | TPO receptor/c-Mpl | TPO receptor/c-Mpl | TPO receptor/c-Mpl | Direct platelet replacement |
| Binding feature | Transmembrane domain of TPO receptor | Peptibody stimulates TPO receptor | TPO receptor agonist | No receptor stimulation |
| Main action | Increases megakaryocyte proliferation and platelet production | Increases megakaryocyte proliferation and platelet production | Increases platelet production | Temporarily increases platelet count |
| Route | Oral | Subcutaneous injection | Oral | Intravenous |
| Major uses | ITP, HCV thrombocytopenia, severe aplastic anemia | ITP and selected thrombocytopenic states | Chronic liver disease procedure-related thrombocytopenia, ITP | Acute severe thrombocytopenia/bleeding support |
| Key adverse concern | Hepatotoxicity, chelation interaction, thrombosis | Thrombosis, marrow reticulin | Thrombosis | Transfusion reactions, alloimmunization |
| Exam point | Separate from polyvalent cations | Weekly injection | Oral TPO-RA without same chelation issue emphasis | Temporary replacement, not production stimulation |
Eltrombopag, romiplostim, and avatrombopag are all thrombopoietin receptor agonists, but their administration and interaction profiles differ. Eltrombopag is oral and has a very important chelation interaction with polyvalent cations. Romiplostim is given by subcutaneous injection. Platelet transfusion provides immediate platelet support but does not stimulate bone marrow platelet production.
MCQs
- Eltrombopag is marketed under which brand name?
a) Promacta
b) Humira
c) Xarelto
d) Keytruda
Answer: a) Promacta
- Eltrombopag belongs to which drug class?
a) Thrombopoietin receptor agonist
b) Antiplatelet drug
c) Factor Xa inhibitor
d) Fibrinolytic agent
Answer: a) Thrombopoietin receptor agonist
- The main receptor stimulated by eltrombopag is:
a) c-Mpl receptor
b) CD20 receptor
c) EGFR receptor
d) Beta-1 receptor
Answer: a) c-Mpl receptor
- c-Mpl is also known as the:
a) Thrombopoietin receptor
b) Insulin receptor
c) Histamine receptor
d) Dopamine receptor
Answer: a) Thrombopoietin receptor
- Eltrombopag mainly increases platelet count by stimulating:
a) Megakaryocyte proliferation and differentiation
b) Platelet destruction
c) Coagulation factor inhibition
d) Plasmin activation
Answer: a) Megakaryocyte proliferation and differentiation
- Eltrombopag interacts with which part of the TPO receptor?
a) Transmembrane domain
b) Nuclear DNA-binding domain
c) Mitochondrial membrane only
d) Ribosomal active site
Answer: a) Transmembrane domain
- Which pathway is activated downstream of TPO receptor stimulation?
a) JAK-STAT pathway
b) GABA pathway
c) Cholinergic pathway
d) Cyclooxygenase pathway only
Answer: a) JAK-STAT pathway
- Eltrombopag is used in persistent or chronic immune thrombocytopenia after insufficient response to:
a) Corticosteroids, immunoglobulins, or splenectomy
b) Insulin only
c) Antibiotics only
d) Antihistamines only
Answer: a) Corticosteroids, immunoglobulins, or splenectomy
- Which condition is also treated with eltrombopag?
a) Severe aplastic anemia
b) Acute asthma attack
c) Hypertensive crisis
d) Bacterial meningitis
Answer: a) Severe aplastic anemia
- Which food or supplement interaction is important with eltrombopag?
a) Polyvalent cations such as calcium, iron, magnesium, and zinc
b) Plain water
c) Simple carbohydrates only
d) Sodium chloride only
Answer: a) Polyvalent cations such as calcium, iron, magnesium, and zinc
- Eltrombopag should generally be separated from:
a) Antacids and dairy products
b) Oxygen inhalation
c) Normal saline
d) Plain glucose tablets only
Answer: a) Antacids and dairy products
- Which serious toxicity is important with eltrombopag?
a) Hepatotoxicity
b) Severe ototoxicity
c) Gingival hyperplasia
d) Bronchospasm as the classic toxicity
Answer: a) Hepatotoxicity
- Excessive platelet rise during eltrombopag therapy may increase risk of:
a) Thrombosis
b) Severe hypoglycemia
c) Cataract cure
d) Bronchodilation
Answer: a) Thrombosis
- Eltrombopag differs from platelet transfusion because eltrombopag:
a) Stimulates platelet production in bone marrow
b) Directly supplies donor platelets
c) Blocks platelet aggregation
d) Dissolves clots
Answer: a) Stimulates platelet production in bone marrow
- Which statement about eltrombopag is correct?
a) It activates the TPO receptor and increases megakaryocyte proliferation and platelet production
b) It inhibits platelet aggregation through P2Y12 blockade
c) It directly dissolves fibrin clots
d) It blocks vitamin K recycling
Answer: a) It activates the TPO receptor and increases megakaryocyte proliferation and platelet production
FAQs
- What is eltrombopag used for?
Eltrombopag is used for persistent or chronic immune thrombocytopenia, thrombocytopenia associated with chronic hepatitis C when interferon therapy is limited by low platelets, and severe aplastic anemia either with immunosuppressive therapy or after inadequate response to immunosuppressive therapy.
- What is the mechanism of action of eltrombopag?
Eltrombopag is a thrombopoietin receptor agonist. It binds the transmembrane domain of the c-Mpl receptor and activates signaling pathways that promote megakaryocyte proliferation, differentiation, maturation, and platelet production.
- Is eltrombopag a steroid?
No. Eltrombopag is not a steroid. It is an oral thrombopoietin receptor agonist that stimulates platelet production in the bone marrow.
- Does eltrombopag work immediately?
No. Eltrombopag does not work like a platelet transfusion. It stimulates platelet production, so platelet counts usually rise gradually over several days to weeks.
- Why should eltrombopag be separated from dairy or minerals?
Eltrombopag can bind polyvalent cations such as calcium, magnesium, iron, aluminum, selenium, and zinc. This chelation reduces absorption and may decrease effectiveness.
- What is the most important safety concern with eltrombopag?
Hepatotoxicity is one of the most important safety concerns. Liver function tests should be monitored before and during therapy.
- Can eltrombopag cause thrombosis?
Yes. If platelet counts rise too high or if a patient has other risk factors, eltrombopag can increase the risk of thrombotic or thromboembolic events.
- Is eltrombopag used to normalize platelet counts?
No. In ITP, the goal is usually to maintain platelet counts at a level that reduces bleeding risk, not to normalize platelets completely.
- How is eltrombopag different from romiplostim?
Eltrombopag is an oral TPO receptor agonist, while romiplostim is given by subcutaneous injection. Both stimulate platelet production through the thrombopoietin receptor pathway.
References
Goodman & Gilman’s The Pharmacological Basis of Therapeutics
Katzung Basic & Clinical Pharmacology
